Andrew Rodriguez writes publicly about using AI to help research treatments for his partner's prolactinoma, drawing on his Columbia biophysics background combined with his venture experience, and this shapes his focus on tools that help patients understand their conditions and make informed care decisions. He stays closely connected to the research community he invests in, taking part in events like the Rewiring Biology hackathon, and was the first investor in Silmaril after knowing founder Aum Upadhyay for nearly seven years, having hired him during Aum's freshman year at Columbia.